As GLP-1 receptor agonists gain popularity for managing type 2 diabetes and obesity, growing numbers of women of reproductive age are conceiving while on these medications , sometimes before they even realize they are pregnant (1 Trusted Source Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis Go to source)
INGREDIENTS: Water, Glycerin, Pentylene Glycol, Niacinamide, 2,3-Butanediol, 1,2-Hexanediol, Glutathione, Betaine, Tromethamine, Gluconolactone, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Ethylhexylglycerin, Sodium Citrate, Sodium Hyaluronate, Sphingomonas Ferment Extract, Citric Acid, 3-O-Ethyl Ascorbic Acid, Melia Azadirachta Flower Extract, Ocimum Sanctum Leaf Extract, Melia Azadirachta Leaf Extract, Curcuma Longa (Turmeric) Root Extract, Corallina Officinalis Extract, Sodium Hyaluronate Crosspolymer, Butylene Glycol, Hydrogenated Lecithin, Xylose, Polyglutamic Acid, Tocopherol, Cholesterol, Dipotassium Glycyrrhizate, Glycine, Cysteine, Sodium Cocoyl Isethionate, Helianthus Annuus (Sunflower) Seed Oil Ingredients subject to change at manufacturer's discretion
Clinical response: Reach out to patients, work to address barriers, and provide motivational support or technical assistance
Why This Matters These findings likely represent just the tip of the iceberg, reinforcing the need for proactive screening, nutrition support, and multidisciplinary care in patients receiving GLP-1 therapy
Patients using oral contraceptives should consider using a non-oral contraceptive method or a backup method for 4 weeks after initiation and after each dose escalation
Always consult with a qualified healthcare provider regarding any medical concerns or before starting any treatment programs
